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BACKGROUND
Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor 
(EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance 
mutations in patients with non–small-cell lung cancer. The efficacy of osimertinib 
as compared with platinum-based therapy plus pemetrexed in such patients is 
unknown.
METHODS
In this randomized, international, open-label, phase 3 trial, we assigned 419 pa-
tients with T790M-positive advanced non–small-cell lung cancer, who had disease 
progression after first-line EGFR-TKI therapy, in a 2:1 ratio to receive either oral 
osimertinib (at a dose of 80 mg once daily) or intravenous pemetrexed (500 mg 
per square meter of body-surface area) plus either carboplatin (target area under 
the curve, 5 [AUC5]) or cisplatin (75 mg per square meter) every 3 weeks for up to 
six cycles; maintenance pemetrexed was allowed. In all the patients, disease had 
progressed during receipt of first-line EGFR-TKI therapy. The primary end point 
was investigator-assessed progression-free survival.
RESULTS
The median duration of progression-free survival was significantly longer with osimer-
tinib than with platinum therapy plus pemetrexed (10.1 months vs. 4.4 months; haz-
ard ratio; 0.30; 95% confidence interval [CI], 0.23 to 0.41; P<0.001). The objective 
response rate was significantly better with osimertinib (71%; 95% CI, 65 to 76) than 
with platinum therapy plus pemetrexed (31%; 95% CI, 24 to 40) (odds ratio for objec-
tive response, 5.39; 95% CI, 3.47 to 8.48; P<0.001). Among 144 patients with metas-
tases to the central nervous system (CNS), the median duration of progression-free 
survival was longer among patients receiving osimertinib than among those receiv-
ing platinum therapy plus pemetrexed (8.5 months vs. 4.2 months; hazard ratio, 
0.32; 95% CI, 0.21 to 0.49). The proportion of patients with adverse events of grade 
3 or higher was lower with osimertinib (23%) than with platinum therapy plus 
pemetrexed (47%).
CONCLUSIONS
Osimertinib had significantly greater efficacy than platinum therapy plus peme-
trexed in patients with T790M-positive advanced non–small-cell lung cancer (includ-
ing those with CNS metastases) in whom disease had progressed during first-line 
EGFR-TKI therapy. (Funded by AstraZeneca; AURA3 ClinicalTrials.gov number, 
NCT02151981.)
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A mong patients with advanced non–small-cell lung cancer with a mutant epi-dermal growth factor receptor (EGFR), 
EGFR tyrosine kinase inhibitors (TKIs) are the 
standard first-line therapy.1-4 Despite high tumor 
response rates with first-line EGFR-TKIs, disease 
progresses in a majority of patients after 9 to 13 
months of treatment.5-12 At the time of progression, 
about 60% of patients (regardless of race or eth-
nic background) are found to have a p.Thr790Met 
point mutation (T790M) in the gene encoding 
EGFR.13-16 The presence of the T790M variant re-
duces binding of first-generation or second-gen-
eration EGFR-TKIs to the ATP-binding pocket of 
EGFR, thereby reducing EGFR-TKI–mediated inhi-
bition of downstream signaling and potentially 
leading to disease progression.17-19
Osimertinib is an oral, irreversible EGFR-TKI 
that is selective for both EGFR and T790M resis-
tance mutations with activity in the central ner-
vous system (CNS).19-21 In the phase 1 component 
of AURA, a phase 1/2 trial (ClinicalTrials.gov num-
ber, NCT01802632), the objective response rate for 
osimertinib in patients with T790M-positive non–
small-cell lung cancer was 61%; the median dura-
tion of progression-free survival was 9.6 months.22 
These findings were confirmed in a pooled analy-
sis of two subsequent phase 2 studies of osimer-
tinib (at a dose of 80 mg once daily) in 411 pa-
tients with T790M-positive non–small-cell lung 
cancer, in which the response rate was 66% on 
blinded independent central review and the me-
dian duration of progression-free survival was 
11.0 months.23 On the basis of these results, the 
Food and Drug Administration approved osimer-
tinib under the Breakthrough Therapy Designa-
tion Program.24 A confirmatory, randomized, open-
label, international, phase 3 trial (AURA3) was 
conducted to show the superiority of osimertinib 
over platinum therapy plus pemetrexed (followed 
by optional pemetrexed maintenance) as standard 
of care for patients with centrally confirmed 
T790M-positive advanced non–small-cell lung can-
cer after first-line EGFR-TKI therapy. Here, we re-
port the results from AURA3.
Me thods
Trial Patients
Eligible patients who were screened at 126 trial cen-
ters from August 2014 through September 2015 
had histologic or cytologic evidence of locally 
advanced or metastatic non–small-cell lung can-
cer and of disease progression after first-line 
EGFR-TKI therapy. The documented presence of 
an EGFR mutation and central confirmation of the 
T790M variant on the cobas EGFR Mutation Test 
(Roche Molecular Systems) after first-line EGFR-
TKI treatment was required. All patients were re-
quired to provide a blood sample at screening to 
test for T790M in plasma circulating tumor DNA 
(ctDNA) on the cobas EGFR Mutation Test, ver-
sion 2. Patients with stable, asymptomatic CNS 
metastases that had not been treated with gluco-
corticoids for at least 4 weeks before the first 
dose of a trial drug were eligible for inclusion. 
Complete eligibility criteria are provided in the 
trial protocol, available with the full text of this 
article at NEJM.org.
Trial Design and Treatment
Patients were stratified according to Asian or 
non-Asian race and were randomly assigned in a 
2:1 ratio to receive oral osimertinib (at a dose of 
80 mg once daily) or intravenous pemetrexed 
(500 mg per square meter of body-surface area) 
plus either carboplatin (target area under the 
curve 5 [AUC5]) or cisplatin (75 mg per square 
meter) every 3 weeks for up to six cycles. Patients 
without disease progression after four cycles of 
platinum therapy plus pemetrexed (platinum–
pemetrexed group) could continue maintenance 
pemetrexed according to the approved label.
Treatment continued until disease progres-
sion, the development of unacceptable side effects, 
or a request by either the patient or the physician 
to discontinue treatment. Patients could receive the 
trial treatment beyond the point of disease pro-
gression (as defined according to the Response 
Evaluation Criteria in Solid Tumors [RECIST], ver-
sion 1.1) as long as they were receiving clinical 
benefit, as judged by the investigator.
According to an amendment to the protocol 
on December 22, 2014, patients who had been 
assigned to receive platinum–pemetrexed could 
cross over to the osimertinib group after objective 
disease progression, according to investigator as-
sessment and as confirmed by blinded indepen-
dent central review. All the patients provided 
written informed consent before screening.
Trial End Points
The primary efficacy end point was the duration 
of progression-free survival as determined by 
investigator assessments, according to RECIST, 
version 1.1. A sensitivity analysis of progression-
A Quick Take 
is available at 
NEJM.org
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free survival by blinded independent central re-
view was conducted. Secondary objectives in-
cluded the response rate according to investigator 
assessment, response duration, disease control 
rate, tumor shrinkage, overall survival, patient-re-
ported outcomes, and safety and side-effect pro-
files. Predefined subgroup analyses included the 
duration of progression-free survival and response 
rate among patients for whom EGFR T790M status 
was determined by means of a plasma ctDNA test 
and among those with CNS metastases.
Assessments
We performed baseline tumor assessments with-
in 28 days after the initiation of the randomized 
treatment, with subsequent assessments per-
formed every 6 weeks until objective disease 
progression. Brain imaging was required only in 
patients with known or suspected CNS metasta-
ses. Assessments for survival were performed 
every 6 weeks after objective disease progression 
or withdrawal from treatment. The duration of 
progression-free survival was defined as the time 
from randomization until the date of objective 
disease progression or death in the absence of 
progression, regardless of whether the patient 
had withdrawn from randomized therapy or 
received another anticancer therapy before pro-
gression. (Details regarding secondary efficacy 
end points are provided in the Supplementary 
Appendix, available at NEJM.org.)
We assessed adverse events using the Na-
tional Cancer Institute Common Terminology 
Criteria for Adverse Events (NCI CTCAE), version 
4.0 (see the Supplementary Appendix for further 
details). Adverse events that were deemed by the 
investigators to be possibly related to a trial regi-
men are described in Table S6 in the Supplemen-
tary Appendix. We assessed patient-reported out-
comes using the European Organization for 
Research and Treatment of Cancer Quality of Life 
Questionnaire–Core 30 items (EORTC QLQ-C30) 
and EORTC QLQ–Lung Cancer 13 items. (Addi-
tional details are provided in the Supplementary 
Methods section in the Supplementary Appendix.)
Trial Oversight
The trial was conducted in accordance with the 
provisions of the Declaration of Helsinki, Good 
Clinical Practice guidelines (as defined by the 
International Conference on Harmonisation), ap-
plicable regulatory requirements, and the policy 
on bioethics and human biologic samples of the 
trial sponsor, AstraZeneca. The trial was designed 
by the principal investigators and the sponsor. 
The sponsor was responsible for the collection 
and analysis of the data and had a role in data 
interpretation. The authors vouch for the com-
pleteness and accuracy of the data and the data 
analyses and adherence to the protocol. This re-
port was written by the first author, with medical-
writing support funded by the sponsor, and was 
reviewed and approved for submission for publi-
cation by all the coauthors and the sponsor. The 
first author had full access to the data and had 
final responsibility for the decision to submit 
the manuscript for publication. The statistical 
analysis plan is available at NEJM.org.
Statistical Analysis
All the patients who underwent randomization 
were included in the intention-to-treat population, 
which was used for all efficacy analyses. The 
safety analysis included all the patients in the 
intention-to-treat population who had received 
at least one dose of a trial drug and for whom 
data were available after the administration of 
the drug.
We used the log-rank test stratified according 
to Asian or non-Asian race to compare the dura-
tion of progression-free survival between the two 
treatment groups. We used the Breslow approach 
for handling tied events and the Kaplan–Meier 
method to summarize the results. Data for pa-
tients who had not had a progression event or had 
not died at the time of the analysis were censored 
at the time of the last RECIST assessment.
We determined that 221 events of progression 
or death would provide a power of 80% to reject 
the null hypothesis of no significant difference 
in the duration of progression-free survival between 
the two treatment groups, assuming a treatment 
effect hazard ratio of 0.67 with a P value of 0.05 
indicating two-sided statistical significance. (Ad-
ditional details are provided in the Supplementary 
Methods section in the Supplementary Appendix.) 
The data cutoff date was April 15, 2016.
R esult s
Patients
Of the 1036 patients who were screened, a total of 
419 patients underwent randomization (279 to 
the osimertinib group and 140 to the platinum–
pemetrexed group) (Fig. S1 in the Supplementary 
Appendix). The demographic and clinical char-
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acteristics of the patients at baseline were bal-
anced in the two groups (Table 1). At the time of 
data cutoff, the mean duration of treatment was 
8.6 months (median, 8.1; range, 0.2 to 18.5) in 
the osimertinib group and 4.8 months (median, 
4.2; range, 0.4 to 14.5) in the platinum–peme-
trexed group. Of the 140 patients in the platinum–
pemetrexed group, 136 (97%) received treatment; 
of these patients, 100 (74%) completed at least 
four cycles of platinum–pemetrexed, with 73 (54%) 
receiving maintenance pemetrexed monotherapy. 
At the time of the data cutoff, 166 patients (59%) 
in the osimertinib group and 16 (12%) in the 
platinum–pemetrexed group were still receiving 
the assigned treatment. Patients who were includ-
ed in the plasma ctDNA analysis are described in 
Figure S2 in the Supplementary Appendix. A total 
of 172 patients with positive results for T790M on 
both tumor and plasma testing were included in 
the analysis.
Post-Trial Treatment
After the discontinuation of randomized treat-
ment, 67 of 279 patients (24%) in the osimer-
tinib group and 96 of 136 patients (71%) in the 
platinum–pemetrexed group received subsequent 
anticancer treatment, including osimertinib, radio-
therapy, platinum and nonplatinum chemother-
apy, and other EGFR-TKIs (Fig. S1 in the Sup-
plementary Appendix). In the platinum–pemetrexed 
group, 82 of 136 patients (60%) crossed over to 
receive osimertinib, with 63 of 82 patients (77%) 
receiving ongoing treatment at the time of data 
cutoff. The subsequent duration of exposure to 
osimertinib ranged from 0.1 months to 12.5 
months (median, 4.2).
Efficacy
Progression-free Survival
At the time of data cutoff, the median follow-up 
for all patients was 8.3 months. Progression 
events occurred in 140 patients (50%) in the 
osimertinib group and in 110 (79%) in the plati-
num–pemetrexed group. The duration of progres-
sion-free survival was significantly longer in the 
osimertinib group than in the platinum–peme-
trexed group (median, 10.1 months vs. 4.4 months; 
hazard ratio after adjustment for Asian or non-
Asian race, 0.30; 95% confidence interval [CI], 
0.23 to 0.41; P<0.001) (Fig. 1A). The estimated 
proportion of patients who were alive and pro-
gression-free at 6 months was 69% (95% CI, 63 
to 74) in the osimertinib group and 37% (95% CI, 
29 to 45) in the platinum–pemetrexed group; at 
12 months, the proportions were 44% (95% CI, 
37 to 51) and 10% (95% CI, 5 to 17), respec-
tively. The duration of progression-free survival 
according to blinded independent central review 
was consistent with the investigator-assessed 
durations, with a median of 11.0 months versus 
4.2 months (adjusted hazard ratio, 0.28; 95% CI, 
0.20 to 0.38; P<0.001). (Additional details are 
provided in the Supplementary Results section 
in the Supplementary Appendix.)
The hazard ratio for progression-free survival 
favored osimertinib across all predefined sub-
groups that were analyzed (hazard ratio, <0.50 for 
each subgroup) (Fig. 2), including patients with 
CNS metastases (median duration of progression-
free survival, 8.5 months vs. 4.2 months; hazard 
ratio, 0.32; 95% CI, 0.21 to 0.49) (Fig. 1B). (Details 
regarding the duration of progression-free survival 
among patients without CNS metastases are pro-
vided in Fig. S3 in the Supplementary Appendix.)
On the basis of mutation status before the 
initiation of the trial, the hazard ratio for pro-
gression-free survival was 0.34 (95% CI, 0.24 to 
0.46) among patients with an EGFR exon 19 dele-
tion and 0.46 (95% CI, 0.30 to 0.71) among those 
with an EGFR L858R mutation. Among Asian pa-
tients, the hazard ratio for progression-free sur-
vival was 0.32 (95% CI, 0.24 to 0.44), as com-
pared with 0.48 (95% CI, 0.32 to 0.75) among 
non-Asian patients. The median duration of pro-
gression-free survival among patients with tumor 
and plasma T790M-positive status was 8.2 months 
in the osimertinib group versus 4.2 months in the 
platinum–pemetrexed group (hazard ratio, 0.42; 
95% CI, 0.29 to 0.61) (Fig. 1C). Among the pa-
tients receiving osimertinib, there was no signifi-
cant difference in benefit between patients with 
T790M-positive status on both tumor and plasma 
analyses and those in the intention-to-treat popu-
lation.
Objective Response and Duration of Response
The response rate was significantly better in the 
osimertinib group (71%; 95% CI, 65 to 76) than 
in the platinum–pemetrexed group (31%; 95% CI, 
24 to 40) (odds ratio, 5.39; 95% CI, 3.47 to 8.48; 
P<0.001) (Table 2). A similar finding was observed 
in the subgroup of patients with T790M-positive 
status on both tumor and plasma analyses (89 of 
116 patients [77%] vs. 22 of 56 patients [39%]; 
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Characteristic
Osimertinib 
(N = 279)
Platinum–Pemetrexed 
(N = 140)
Median age (range) — yr 62 (25–85) 63 (20–90)
Female sex — no. (%) 172 (62) 97 (69)
Race — no. (%)†
White 89 (32) 45 (32)
Asian 182 (65) 92 (66)
Other 8 (3) 3 (2)
No history of smoking — no. (%) 189 (68) 94 (67)
Disease classification — no. (%)
Adenocarcinoma histology not otherwise specified 232 (83) 122 (87)
Metastatic disease 266 (95) 138 (99)
CNS metastases‡ 93 (33) 51 (36)
Extrathoracic visceral metastases§ 145 (52) 80 (57)
Type of EGFR mutation — no. (%)¶
T790M‖ 275 (99) 138 (99)
Exon 19 deletion 191 (68) 87 (62)
Exon 21 L858R 83 (30) 45 (32)
G719X 4 (1) 2 (1)
S768I 1 (<1) 1 (1)
Exon 20 insertion 1 (<1) 2 (1)
No. of previous anticancer regimens for advanced disease — 
no. (%)**
1 269 (96) 134 (96)
2 9 (3) 6 (4)
3 1 (<1)†† 0
Previous EGFR-TKI therapy — no. (%) 279 (100) 139 (99)
Gefitinib 166 (59) 87 (62)
Erlotinib 96 (34) 49 (35)
Afatinib 20 (7) 4 (3)
*  CNS denotes central nervous system, EGFR epidermal growth factor receptor, and TKI tyrosine kinase inhibitor.
†  Race was self-reported. The category of “other” includes black, American Indian, and Alaska Native.
‡  CNS metastases were determined from baseline data for the CNS lesion site, medical history, surgery, or radiotherapy. 
One patient was identified as having locally advanced disease in the brain.
§  Extrathoracic visceral metastases were determined on the basis of baseline data for which the disease site was de-
scribed as adrenal, ascites, brain or CNS, gastrointestinal, genitourinary, hepatic (including gallbladder), liver, other 
CNS, pancreas, peritoneum, or spleen. Also included were other metastatic sites, such as those occurring in the eye 
and thyroid, as identified as extrathoracic visceral sites by AstraZeneca physicians.
¶  EGFR mutations were identified by means of the cobas EGFR Mutation Test from a biopsy sample obtained after con-
firmation of disease progression while the patient was receiving the most recent treatment regimen.
‖  Six patients (four in the osimertinib group and two in the platinum–pemetrexed group) did not have centrally con-
firmed T790M mutation–positive status that was documented in the trial database. Three patients (two in the osimer-
tinib group and one in the platinum–pemetrexed group) were subsequently found to have positive results on testing 
for the T790M mutation. Therefore, three patients (two in the osimertinib group and one in the platinum–pemetrexed 
group) were T790M-negative in the tumor sample and underwent randomization in error. One of the three patients 
who had T790M-negative results in the tumor sample had T790M-positive results in plasma.
**  Patients were classified as having received more than one previous line of therapy if they received any of the follow-
ing: adjuvant or neoadjuvant chemotherapy administered less than 6 months before the start of EGFR-TKI therapy; 
more than one EGFR-TKI (switching from a first-generation EGFR-TKI to a second-generation EGFR-TKI, or restarting 
EGFR-TKI after >12 months off treatment) administered sequentially; or the addition of anticancer agents such as cy-
totoxic chemotherapy or a c-Met monoclonal antibody toward the end of a previous monotherapy EGFR-TKI regimen.
††  One patient in the osimertinib group was treated with fulvestrant followed by letrozole before starting EGFR-TKI.
Table 1. Demographic and Clinical Characteristics of the Patients at Baseline.*
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odds ratio, 4.96; 95% CI, 2.49 to 10.15; P<0.001). 
Among the patients who had a response to treat-
ment at the time of data cutoff, disease progres-
sion or death was reported in 88 of 197 patients 
(45%) in the osimertinib group and in 36 of 44 
patients (82%) in the platinum–pemetrexed group. 
On the basis of investigator assessment, the me-
dian response duration was 9.7 months (95% CI, 
8.3 to 11.6) in the osimertinib group and 
4.1 months (95% CI, 3.0 to 5.6) in the platinum–
pemetrexed group. Data regarding the best per-
centage change from baseline in target lesions 
are provided in Figure S4 in the Supplementary 
Appendix. At the time of data cutoff, 61 patients 
(15%) had died: 35 (13%) in the osimertinib group 
and 26 (19%) in the platinum–pemetrexed group. 
Data for the overall survival analysis were not 
complete at the time of this report.
Patient-Reported Outcomes
In a mixed model for repeated-measures analy-
sis, patient-reported outcomes were better in the 
osimertinib group than in the platinum–peme-
trexed group across five prespecified symptoms 
during the overall period from randomization 
until 6 months (Table S4 in the Supplementary 
Appendix).
Safety and Adverse Events
Adverse events occurred in 273 of 279 patients 
(98%) in the osimertinib group and in 135 of 
136 (99%) in the platinum–pemetrexed group. 
Adverse events with a maximum grade of 1 were 
reported in 93 patients (33%) in the osimertinib 
group and in 15 (11%) in the platinum–pemetrexed 
group; adverse events with a maximum grade of 
2 were reported in 117 (42%) and in 56 (41%), 
respectively. Fewer patients reported adverse events 
of grade 3 or more in the osimertinib group than 
in the platinum–pemetrexed group (63 [23%] vs. 
64 [47%]). A summary of adverse events of grade 
3 or more is provided in Table S5 in the Supple-
mentary Appendix. (Details regarding the safety 
analysis for patients who crossed over from plati-
num–pemetrexed to osimertinib are provided in 
the Supplementary Results section in the Supple-
mentary Appendix.)
In the osimertinib group, the most com-
monly reported adverse events were diarrhea (in 
113 patients [41%]), rash (in 94 [34%]), dry skin 
(in 65 [23%]), and paronychia (in 61 [22%]) 
(Table 3). The most commonly reported adverse 
events in the platinum–pemetrexed group were 
nausea (in 67 patients [49%]), decreased appetite 
(in 49 [36%]), constipation (in 47 [35%]), and ane-
mia (in 41 [30%]). Adverse events that were deemed 
by the investigators to be possibly related to a trial 
regimen are described in Table S6 in the Supple-
mentary Appendix.
Interstitial lung disease–like adverse events 
were reported in 10 patients (4%) in the osimer-
tinib group (nine events of grade 1 or 2 in sever-
ity and one death) and in 1 patient (1%) in the 
platinum–pemetrexed group (one grade 3 event). 
A prolongation in the QT interval was recorded 
in 10 patients (4%) in the osimertinib group and 
1 patient (1%) in the platinum–pemetrexed group, 
with all events of grade 1 or 2 in severity except 
for one grade 3 event in the osimertinib group. 
(Additional details are provided in the Supple-
mentary Results section in the Supplementary 
Appendix.)
Osimertinib was associated with a lower rate 
of adverse events leading to permanent discon-
tinuation than was platinum–pemetrexed (in 
19 patients [7%] and 14 patients [10%], respec-
tively). Fatal adverse events were reported in 4 pa-
tients in the osimertinib group (respiratory failure 
in 2, pneumonitis in 1, and ischemic stroke in 
1). One fatal adverse event of hypovolemic shock 
was reported in the platinum–pemetrexed group.
Discussion
In this trial, we found that patients with T790M-
positive advanced non–small-cell lung cancer who 
Figure 1 (facing page). Duration of Progression-free 
Survival, According to Subgroup.
Shown are Kaplan–Meier estimates of the duration of 
progression-free survival as assessed by investigators 
in the intention-to-treat population (Panel A), in pa-
tients with central-nervous-system (CNS) metastases 
(Panel B), and in patients with EGFR T790M–positive 
status in both tumor and plasma (Panel C). The tick 
marks indicate censored data. Progression events that 
occurred after two or more missed visits (i.e., 14 weeks) 
after the last assessment were censored at the last as-
sessment, according to Response Evaluation Criteria in 
Solid Tumors. CI denotes confidence interval.
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received osimertinib had better response rates 
and a longer duration of progression-free sur-
vival than did those receiving platinum therapy 
plus pemetrexed after first-line EGFR-TKI thera-
py. The progression-free survival benefit with 
osimertinib was observed across all predefined 
subgroups, with hazard ratios of less than 0.50, 
including in patients with asymptomatic CNS 
metastases. In five prespecified measures of pa-
tient-reported symptoms, osimertinib had better 
results than platinum–pemetrexed.
Among patients receiving osimertinib, the 
AURA3 outcomes (median progression-free sur-
vival duration of 10.1 months and response rate 
of 71%) were in line with results of the phase 1/2 
AURA and AURA2 studies.22,23 Similarly, the 
treatment outcomes with platinum–pemetrexed 
(a median progression-free survival duration of 
4.4 months and response rate of 31%) were 
broadly in line with cisplatin–pemetrexed treat-
ment in a T790M-positive population (as defined 
according to the results on a plasma ctDNA test) 
in the IMPRESS trial.25 Chemotherapy was the 
standard control at the time of trial initiation. 
As evidence emerges on immunotherapy, future 
studies are needed to address the role of such 
therapy among patients with EGFR mutation–
positive non–small-cell lung cancer.
The findings of AURA3 support the feasibil-
ity of detecting EGFR T790M from plasma ctDNA 
samples, in line with previous reports.26,27 Im-
provement in outcomes with osimertinib over 
platinum–pemetrexed in the tumor and plasma 
ctDNA T790M-positive subgroup was similar to 
Figure 2. Subgroup Analyses of Progression-free Survival.
A hazard ratio of less than 1 indicates a lower risk of progression in the osimertinib group. The Cox proportional-
hazards model includes randomized treatment, the subgroup covariate of interest, and the treatment according to 
subgroup interaction. The size of the circles is proportional to the number of events. Overall population analyses 
are presented from both a Cox proportional-hazards model and the primary analysis (U and V statistics from a log-
rank test stratified according to race). If there were fewer than 20 events in any subgroup, then the analysis was not 
performed. The shaded area indicates the 95% CI for the overall hazard ratio (all patients). NC denotes could not 
be calculated.
0.20.1 0.3 0.4 0.5 0.6 0.8 1.0
Overall
Cox proportional-hazards model
Log-rank test
Race
Asian
Non-Asian
Sex
Male
Female
Age at screening
<65 yr
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Duration of previous EGFR-TKI therapy
<6 mo
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CNS metastases
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Smoking history
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No
419
274
145
150
269
242
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279
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395
144
275
136
283
Hazard Ratio (95% CI)Subgroup No. of Patients
0.40 (0.29–0.55)
0.40 (0.27–0.62)
0.36 (0.26–0.49)
0.46 (0.30–0.71)
0.39 (0.30–0.51)
NC
0.32 (0.21–0.49)
0.34 (0.24–0.46)
0.38 (0.28–0.54)
0.34 (0.23–0.50)
0.43 (0.28–0.65)
0.34 (0.25–0.47)
0.48 (0.32–0.75)
0.32 (0.24–0.44)
0.30 (0.23–0.41)
0.37 (0.29–0.48)
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that in the intention-to-treat population. How-
ever, because of the high false negative rates 
with plasma ctDNA T790M testing, the analysis 
of a biopsy sample is recommended for patients 
with a plasma T790M-negative result who have 
disease progression after receiving first-line 
EGFR-TKI.26 We cannot address clinical outcomes 
of patients with potential false positive results 
Response
Osimertinib 
(N = 279)
Platinum–Pemetrexed 
(N = 140)
Odds Ratio 
(95% CI)† P Value‡
Type of response — no. (%)
Complete  4 (1) 2 (1)
Partial 193 (69) 42 (30)
Stable disease for ≥6 wk  63 (23) 60 (43)
Progression 18 (6) 26 (19)
RECIST progression 15 (5) 22 (16)
Death  3 (1) 4 (3)
Could not be evaluated   1 (<1) 10 (7)
Objective response rate 5.39 (3.47–8.48) <0.001
Percentage of patients 71 31
95% CI 65–76 24–40
Disease control rate§ 4.76 (2.64–8.84) <0.001
Percentage of patients 93 74
95% CI 90–96 66–81
Time to response¶
Median no. of wk 6.1 6.4
95% CI NC–NC 6.3–7.0
≤6 wk after randomization 
— no./total no. (%)‖
161/197 (82) 29/44 (66)
Duration of response**
Median no. of months 9.7 4.1
95% CI 8.3–11.6 3.0–5.6
>6 mo — no./total no. (%) 96/197 (49) 12/44 (27)
>9 mo — no./total no. (%) 56/197 (28) 4/44 (9)
>12 mo — no./total no. (%) 21/197 (11) 1/44 (2)
*  Tumor responses were assessed by the investigators according to Response Evaluation Criteria in Solid Tumors 
(RECIST), version 1.1. Complete response and partial response did not require confirmation, according to RECIST, 
version 1.1., guidance on randomized studies, since the control group served as an appropriate means of interpreta-
tion of data. CI denotes confidence interval, and NC could not be calculated.
†  Odds ratios were calculated with the use of logistic regression adjusted for Asian or non-Asian race. An odds ratio of 
more than 1 favors osimertinib.
‡  P values were calculated by means of the likelihood ratio test, which compared two models (one model with race as 
the only covariate and the other model with both treatment factor and race as covariates).
§  The disease control rate is the proportion of patients who had a complete response, a partial response, or stable dis-
ease lasting at least 6 weeks before any disease-progression event.
¶  The time to tumor response was calculated from the date of randomization to the date of the first documentation of 
a partial or complete response.
‖  A 1-week window was allowed at approximately 6 weeks.
**  The duration of response was calculated with the use of the Kaplan–Meier method from the time of the first docu-
mented response until the date of progression or the last RECIST assessment for patients who did not have disease 
progression.
Table 2. Response to Treatment (Intention-to-Treat Population).*
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(i.e., T790M-positive results on plasma ctDNA 
testing and negative results on tumor testing) in 
this trial because of the requirement for a posi-
tive tumor sample for enrollment.
In the BLOOM study (NCT02228369), in 
which 20 patients with leptomeningeal metasta-
ses from EGFR mutation–positive non–small-cell 
lung cancer were treated with osimertinib (at a 
dose of 160 mg once daily), preliminary results 
showed radiologic improvement in 7 patients.21 
In our trial, the benefit of osimertinib in the 
subgroup of patients with CNS metastases was 
shown by a longer duration of progression-free 
survival than among those treated with plati-
num–pemetrexed. Independent radiologic assess-
ment of all intracranial metastases is ongoing.
Adverse Event
Osimertinib 
(N = 279)
Platinum–Pemetrexed 
(N = 136)
Any Grade Grade ≥3 Any Grade Grade ≥3
number (percent)
Diarrhea 113 (41) 3 (1) 15 (11) 2 (1)
Rash† 94 (34) 2 (1) 8 (6) 0
Dry skin† 65 (23) 0 6 (4) 0
Paronychia† 61 (22) 0 2 (1) 0
Decreased appetite 50 (18) 3 (1) 49 (36) 4 (3)
Cough 46 (16) 0 19 (14) 0
Nausea 45 (16) 2 (1) 67 (49) 5 (4)
Fatigue 44 (16) 3 (1) 38 (28) 1 (1)
Stomatitis 41 (15) 0 21 (15) 2 (1)
Constipation 39 (14) 0 47 (35) 0
Pruritus 35 (13) 0 6 (4) 0
Vomiting 31 (11) 1 (<1) 27 (20) 3 (2)
Back pain 29 (10) 1 (<1) 12 (9) 1 (1)
Thrombocytopenia† 28 (10) 1 (<1) 27 (20) 10 (7)
Nasopharyngitis 28 (10) 0 7 (5) 0
Headache 28 (10) 0 15 (11) 0
Dyspnea 24 (9) 3 (1) 18 (13) 0
Neutropenia† 22 (8) 4 (1) 31 (23) 16 (12)
Leukopenia† 22 (8) 0 20 (15) 5 (4)
Anemia† 21 (8) 2 (1) 41 (30) 16 (12)
Asthenia 20 (7) 3 (1) 20 (15) 6 (4)
Pyrexia 18 (6) 0 14 (10) 0
Alanine aminotransferase elevation 18 (6) 3 (1) 15 (11) 1 (1)
Aspartate aminotransferase elevation 14 (5) 3 (1) 15 (11) 1 (1)
Malaise 11 (4) 0 14 (10) 0
*  Listed are adverse events that were reported in at least 10% of the patients in any group. Safety analyses included all 
the patients who received at least one dose of a trial drug (safety analysis set). Included are adverse events with an on-
set date on or after the date of first dose and up to and including 28 days after the discontinuation of the trial drug or 
the day before the first administration of crossover treatment. Some patients had more than one adverse event.
†  This category represents a grouped term for the event. If a patient had multiple preferred-term level events within a 
specific grouped term adverse event, then the maximum grade (according to the Common Terminology Criteria for 
Adverse Events) across those events was counted.
Table 3. Adverse Events.*
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In AURA3, the safety profile for osimertinib 
was consistent with that reported previously and 
differed from that in the platinum–pemetrexed 
group.23 The safety profile in the platinum–
pemetrexed group was consistent with that ob-
served in the cisplatin–pemetrexed group in the 
IMPRESS trial.28 Overall, adverse events tended 
to be more severe in the platinum–pemetrexed 
group, despite the longer treatment duration with 
osimertinib.
In conclusion, osimertinib was more effective 
than combination platinum-based chemotherapy 
in patients with T790M-positive non–small-cell 
lung cancer (including those with CNS metastases) 
after disease progression with first-line EGFR-TKI 
therapy.
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